Checkpoint inhibitors, specifically those targeting Cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and Programmed cell death protein-1 (PD-1/PD-L1) pathways, work by blocking the inhibitory signals that cancer cells use to evade immune detection [1]. The gene discussed is CTLA4; the disease is cancer.